Oral Antibiotic Prescription for Clinically Infected Burns
For a clinically infected burn without drug allergies, prescribe oral clindamycin 300-450 mg three times daily or trimethoprim-sulfamethoxazole (TMP-SMX) 1-2 double-strength tablets twice daily, with treatment duration of 7-14 days based on clinical response.
Rationale and Treatment Algorithm
The choice of oral antibiotic for infected burns hinges on covering the most likely pathogens—primarily Staphylococcus aureus (including MRSA) and Streptococcus species—while accounting for local resistance patterns and burn-specific considerations.
Primary Oral Antibiotic Options
According to IDSA guidelines for complicated skin and soft tissue infections (which include infected burns), the recommended oral agents for empirical MRSA coverage are 1, 2, 3:
- Clindamycin 300-450 mg orally three times daily (A-II evidence)
- TMP-SMX 1-2 double-strength tablets twice daily (A-II evidence)
- Doxycycline or minocycline 100 mg twice daily (A-II evidence)
- Linezolid 600 mg twice daily (A-II evidence, but expensive)
Decision Framework
If local MRSA prevalence is >20% OR the patient has MRSA risk factors (recent hospitalization, prior MRSA infection, injection drug use, recent antibiotics):
- Start with clindamycin as first choice if local clindamycin resistance is <10% 1, 2
- Use TMP-SMX if clindamycin resistance is high, though note TMP-SMX lacks streptococcal coverage 1, 2
- Consider doxycycline as alternative 3
If streptococcal coverage is also needed (non-purulent cellulitis component):
- Clindamycin alone provides both MRSA and streptococcal coverage (A-II) 1, 2
- TMP-SMX or doxycycline PLUS amoxicillin for dual coverage (A-II) 1, 2
If MRSA is unlikely (no risk factors, local prevalence <20%):
Critical Caveats
Avoid tetracyclines in children <8 years due to tooth discoloration risk (A-II) 1, 2, 3
Clindamycin resistance concerns: Inducible resistance can occur in erythromycin-resistant MRSA strains. If clindamycin is chosen, ensure D-test is performed if susceptibility testing shows erythromycin resistance 1, 3, 4.
TMP-SMX limitations: Poor anaerobic and streptococcal coverage means it should be combined with a beta-lactam if non-purulent cellulitis is present 1, 2.
Burn-specific considerations: While guidelines address infected burns as complicated SSTIs 1, 2, evidence specifically for oral antibiotics in burns is limited. Most burn infection data focuses on topical agents or systemic IV therapy for severe infections 5, 6. Routine antibiotic prophylaxis is NOT recommended for burns 6, 7—antibiotics should only be used when clinical infection is documented.
Treatment Duration
5-10 days for mild-moderate infections, individualized based on clinical response 1, 2. 7-14 days for complicated infections including burns 1, 2, 3.
When Oral Therapy is Insufficient
If the patient has systemic signs of infection (fever, hypotension, tachycardia, elevated WBC), extensive burns (>20% TBSA), or fails to improve within 48-72 hours, transition to IV therapy with vancomycin, linezolid, or daptomycin and consider hospitalization 1, 2, 3.
The evidence strongly supports empirical MRSA coverage for infected burns given the high prevalence of community-associated MRSA in skin infections, with clindamycin and TMP-SMX representing the most cost-effective and well-studied oral options.